Background Globally, India has the world's highest burden of multidrug-resistant
tuberculosis (MDR-TB). Programmatic Management of Drug Resistant TB (PMDT) in India …

Rationale: Until 2020, extensively drug-resistant tuberculosis (XDR-TB) was defined as TB
with resistance to rifampicin and isoniazid (multidrug-resistant TB [MDR-TB]), any …

Background Recent World Health Organization guidance on drug-resistant tuberculosis
treatment de-prioritised injectable agents, in use for decades, and endorsed all-oral longer …

Setting Nationwide Canadian public health surveillance. Objective Description of
demographic features and disease characteristics of drug-resistant tuberculosis (TB) in …

Objective: To evaluate the treatment outcome of second line drugs used in directly observed
treatment, short‑course (DOTS)‑Plus regimen under Revised National Tuberculosis Control …

Objectives To describe long-term treatment outcomes in patients with multi-drug-
resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) and validate established outcome …

Highlights•Despite programmatic efforts, high death and loss to follow up rates are
alarming.•Ofloxacin resistance and baseline low body weight emerged as risk factors for …

Tuberculosis (TB) differs from most other bacterial infectious diseases by a very long
duration of combination antibiotic therapy required to achieve relapse-free cure. Although …

Background The fixed-dose combination (FDC) for first-line antituberculosis (TB) treatment
has long been a standard practice worldwide; however, there is limited evidence on whether …

We identify early predictors of multidrug-resistant tuberculosis and describe improved
clinical outcomes, including survival, for patients with human immunodeficiency virus (HIV) …